Biological therapy of breast cancer

BioDrugs

Volumn 14, Issue 4, 2000, Pages 221-246

  Park, John W ^a   Tripathy, Debasish ^a   Campbell, Michael J ^a   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BATIMASTAT; BEXAROTENE; BMS 182248; CANCER VACCINE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FENRETINIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLIPOSOME; IMMUNOTOXIN; M MONOCLONAL ANTIBODY 225; MDX 210; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2B1; NAVELBINE; PACLITAXEL; PARACETAMOL; PRINOMASTAT; RETINOID; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG INDUCED DISEASE; GENE THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0033755498     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014040-00003     Document Type: Review

References (274)

1. Shih C, Padhy LC, Murray M, et al. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290 (5803): 261-4
2. Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312 (5994): 513-6
3. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p!85. Cell 1986; 45 (5): 649-57
4. Semba K, Kamata N, Toyoshima K, et al. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB- I/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 1985; 82(19): 6497-501
5. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229 (4717): 974-6
6. Schlechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229 (4717): 976-8
7. Lemoine NR, Staddon S, Dickson C, et al. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 1990; 5 (2): 237-9
8. Fukushige S, Matsubara K, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6 (3): 955-8
9. Di Fiore PP. Pierce JH, Kraus MH, et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237 (4811): 178-82
10. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p!85HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 1987; 84: 7159-63
11. Muller WJ, Sinn E, Pattengale PK, et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988; 54 (1): 105-15
12. Guy CT, Webster MA, Schaller M, et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89: 10578-82
13. Lucchini F, SaccoMG, Hu N, et al. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett 1992; 64 (3): 203-9
14. Bouchard L, Lamarre L, Tremblay PJ, et al. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989; 57 (6): 931-6
15. Suda Y, Aizawa S, Furuta Y, et al. Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659-Glu659). Embo J 1990; 9 ( 1 ): 181 -90
16. Slamon DJ, Clark GM, Wong SO, et al. Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 1987; 235: 177-82
17. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12
18. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER-2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999; 26 Suppl. 12: 108-16
19. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992; 24: 85-95
20. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10 (12): 2435-46
21. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6
22. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60
23. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-70
24. Hayes DF. Should we treat HER, too? J Clin Oncol 1996; 14; 697-9
25. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5: 953-62
26. Niehans GA, Singleton TP, Dykoski D, et al. Stability of HER2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 1993; 85: 1230-5
27. van Leeuwen F, van de Vijver MJ, Lomans J, et al. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. Oncogene 1990; 5 (4): 497-503
28. Myers JN, Drebin JA, Wada T, et al. Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p)85neu. Methods Enzymol 1991; 198 (1): 277-90
29. Kasprzyk PG, Song SU, Di Fiore PP, et al. Therapy of an animal model of human gastric cancer using a combination of antierbB-2 monoclonal antibodies. Cancer Res 1992; 52 (10): 2771-6
30. Klapper LN, Vaisman N, Hurwitz E, et al. A subclass of tumorinhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997; 14 (17): 2099-109
31. Yen L, Nie ZR, You XL, et al. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing pi 85 (erbB-2) is dependent on the ras signaling pathway. Oncogene 1997; 14(15): 1827-35
32. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-pi85HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37: 255-63
33. Park JW, Stagg R, Lewis CD, et al. Anti-pi 85HER2 monoclonal antibodies: biological properties and potential for immunotherapy. In: Dickson RB, Lippman ME, editors. Genes, oncogenes, and hormones: advances in cellular and molecular biology of breast cancer. Boston: Kluwer Academic Publishers, 1992: 193-211
34. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing breast cancer xenografts. Cancer Res 1998; 58: 2825-31
35. Carter P, Presta L, German CM, et al. Humanization of an antipi 85HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9
36. Sliwkowski MX, Lofgren JA, Lewis GD, et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70
37. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-pi85HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14 (3): 737-44
38. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-pi85HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing meta-static breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16 (8): 2659-71
39. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48
40. Vogel CL, Cobleigh M, Tripathy D, et al. Efficacy and safety of Herceptin (Trastuzumab, humanized anti-HER-2 antibody) as a single agent in first-line treatment of HER-2 overexpressing metastatic breast cancer (HER-2+/MBC). Breast Cancer Res Treat 1998; 50: 232a
41. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17: 98a
42. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER2 monoclonal antibody Herceptin in HER2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 127a
43. Hudis C, Seidman A, Paton V, et al. Characterization of cardiac dysfunction observed in the Herceptin (trastuzumab) clinical trials. Breast Cancer Res Treat 1998; 50: 232a
44. Fornier M, Seidman AD, Esteva FJ, et al. Weekly (W) Herceptin (H) + 1 hour taxol (T): phase II study in HER2 overexpressing (H2+) and non-overexpressing (H2-) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999; 18: 126a
45. Burstein HJ, Kuter I, Richardson PG, et al. Herceptin (H) and vinorelbine (V) as second-line therapy for HER2-positive (HER2+) metastatic breast cancer (MBC) [abstract 18]. Breast Cancer Res Treat 1999; 57: 29
46. Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the proto-oncogene HER2/neu. J Clin Oncol 1995; 13: 2281-92
47. Weiner LM, Holmes M, Adams GP, et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 1993: 53: 94-100
48. Weiner LM, Clark JI, Davey M, et al. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res 1995; 55 (20): 4586-93
49. Pai-Scherf LH, Villa J, Pearson D, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999: 5 (9): 2311-5
50. Park JW, Hong K, Kirpotin DB, et al. Immunoliposomes for cancer treatment. Adv Pharmacol 1997; 40: 399-435
51. Park JW, Kirpotin D, Shalaby R, et al. Anti-HER2 immunoliposomes: significantly superior efficacy vs. doxorubicin, liposomal doxorubicin, and anti-her2 antibody treatment, via novel mechanism of action. Proc Am Soc Clin Oncol 1998: 17: 216a
52. Park JW, Hong K, Carter P, et al. Development of antipi 85HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995; 92: 1327-31
53. Kirpotin D, Park JW, Hong K. et al. Sterically stabilized antiHER2 immunoliposomes: design and targeting to human breast cancer cell in vitro. Biochemistry 1997; 36: 66-75
54. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 1997; 118(2): 153-60
55. Sainsbury JR, Malcolm AJ, Appleton DR, et al. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 1985; 38 (11): 1225-8
56. Klijn GGM, Berns PMJJ, Schmilz P1M, et al. The clinical significance of epidermal growth factor receptor (EGFR) in human breast cancer: a review of 5232 patients. Endocrinol Rev 1992; 13:3-17
57. Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984; 259 (12): 7755-60
58. Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr 1992; 13: 125-31
59. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85(16): 1327-33
60. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53 (19): 4637-42
61. Prewett M, Rockwell P, Rockwell RF, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996; 19 (6): 419-27
62. Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998; 4 (12): 2957-66
63. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3(12Pt2): 2703-7
64. Marken JS, Schieven GL, Hellstrom I, et al. Cloning and expression of the tumor-associated antigen L6. Proc Natl Acad Sci U S A 1992; 89 (8): 3503-7
65. Goodman GE, Hellstrom I, Brodzinsky L, et al. Phase 1 trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990; 8 (6): 1083-92
66. Ziegler LD, Palazzolo P, Cunningham J, et al. Phase 1 trial of murine monoclonal antibody L6 in combination with subcutaneous interleukin-2 in patients with advanced carcinoma of the breast, colorectum, and lung. J Clin Oncol 1992; 10 (9): 1470-8
67. Goodman GE, Hellstrom I, Yelton DE, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993; 36 (4): 267-73
68. Denardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997; 17 (3B): 1745-51
69. Trail PA, WillnerD, Lasch SJ, et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates [published erratum appears in Science 1994 Feb 25; 263 (5150): 1076]. Science 1993; 261 (5118): 212-5
70. Sjogren HO, Isaksson M, Willner D, et al. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 1997; 57 (20): 4530-6
71. Saleh MM, Sugarman S, Murray J, et al. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol2000; 18 (11): 2282-92
72. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 1999; 17 (2): 478-84
73. Campbell MJ, Carroll W, Kon S, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987; 139 (8): 2825-33
74. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 1988; 141 (9): 3227-33
75. Campbell MJ, Esserman L, Byars NE, et al. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol 1989; 4 (4): 251-70
76. Campbell MJ, Esserman L, Byars NE, et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol 1990; 145 (3): 1029-36
77. Kaminski MS, Kitamura K, Maloney DG, et al. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J Immunol 1987; 138 (4): 1289-96
78. Kwak LW, Campbell MJ, Zelenetz AD, et al. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumorderived idiotypic immunoglobulin. Blood 1990; 76 (11): 2411-7
79. Tao MH, Levy R. Idiotype/granulocyte-macrophage colonystimulating factor fusion protein as a vaccine for B-cell lymphoma [see comments]. Nature 1993; 362 (6422): 755-8
80. Kwak LW, Campbell MJ, Czerwinski DK, et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors [see comments]. N EnglJ Med 1992;327(17): 1209-15
81. Hsu FJ, Kwak L, Campbell M, et al. Clinical trials of idiotypespecific vaccine in B-cell lymphomas. Ann N Y Acad Sci 1993; 690: 385-7
82. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 1997; 89 (9): 3129-35
83. Biragyn A, Kwak LW. B-cell malignancies as a model for cancer vaccines: from prototype protein to next generation genetic chemokine fusions. Immunol Rev 1999; 170: 115-26
84. Biragyn A, Tani K, Grimm MC, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell de-pendent antitumor immunity [see comments]. Nat Biotechnol 1999; 17 (3): 253-8
85. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments]. Nature Med 1999; 5 (10): 1171-7
86. Kwak LW, Pennington R, Boni L, et al. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 1998; 160 (8): 3637-41
87. Kobrin CB, Kwak LW. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest 1997; 15 (6): 577-87
88. Caspar CB, Levy S, Levy R. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 1997; 90 (9): 3699-706
89. McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A 1999; 96 (2): 703-8
90. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-29
91. Bystryn JC. Vaccines for melanoma. Design strategies and clinical results. Dermatol Clin 1998; 16 (2): 269-75
92. Ollila DW, Kelley MC, Gammon G, et al. Overview of melanoma vaccines: active specific immunotherapy for melanoma patients. Semin Surg Oncol 1998; 14 (4): 328-36
93. Gajewski TF, Fallarino F. Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol 1995; 2 (4): 211-25
94. Conforti AM, Ollila DW, Kelley MC, et al. Update on active specific immunotherapy with melanoma vaccines. J Surg Oncol 1997; 66(1): 55-64
95. Kühn CA, Hanke CW. Current status of melanoma vaccines. Dermatol Surg 1997; 23 (8): 649-54; discussion 54-5
96. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27
97. Burnet FM. Immunological surveillance in neoplasia. Transplant Rev 1971; 7: 3-25
98. Burnet FM. Implications of immunological surveillance for cancer therapy. Isr J Med Sci 1971 ; 7 ( 1 ): 9-16
99. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996; 8 (5): 271-80
100. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045
101. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gplOO is recognized by melanoma- derived tumor-infiltrating lymphocytes. J Exp Med 1994; 179 (3): 1005-9
102. Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179 (3): 921-30
103. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180 ( I ): 347-52
104. Disis ML, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54 ( 1 ): 16-20
105. Fisk B, Blevins TL, Wharton JT, et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181 (6): 2109-17
106. Peoples GE, Goedegebuure PS, Smith R, et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995; 92 (2): 432-6
107. Disis ML, Cheever MA. Oncogenic proteins as tumor antigens. Curr Opin Immunol 1996; 8 (5): 637-42
108. Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994; 54 (13): 3387-90
109. Cheever MA, Disis ML, Bernhard H, et al. Immunity to oncogenic proteins. Immunol Rev 1995; 145: 33-59
110. Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER- 2/neu+ tumors. Cancer Res 1998; 58 (21): 4902-8
111. Disis ML, Grabstein KH, Sleath PR, et al. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5 (6): 1289-97
112. Ernster VL, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast (see comments]. JAMA 1996; 275 (12): 913-8
113. Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990; 70 (4): 853-71
114. VandeVijver MJ, Peterse ML, Mooi WJ, et al. Neu-protein expression in breast cancer. N Engl J Med 1988:319: 1239-45
115. Liu E, Thor A, He M, et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992; 7: 1027-32
116. Solin LJ, Kurtz J, Fourquet A, et al. Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 1996; 14(3): 754-63
117. Esserman LJ, Lopez T, Montes R, et al. Vaccination with the extracellular domain of plSSneu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother 1999; 47 (6): 337-42
118. Disis ML, Gralow JR, Bernhard H, et al. Peptide-based. but not whole protein, vaccines elicit immunity to HER- 2/neu, oncogenic self-protein. J Immunol 1996; 156 (9): 3151-8
119. Nagata Y, Furugen R, Hiasa A, et al. Peptides derived from a wild-type murine proto-oncogene c-erbB- 2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159(3): 1336-43
120. Roussel P, Lamblin G, Lhermitte M, et al. The complexity of mucins. Biochimie 1988; 70: 1471-82
121. Strouss G, Deker J. Mucin-type glycoproteins. Crit Rev Biochem Mol Biol Int 1992; 27: 57-92
122. McGuckin M, Walsh M, Hohn B, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995:26:432-9
123. Kinney A, Sahin A, Vernon S, et al. The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997; 80: 2240-9
124. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995:57:607-34
125. Xing PX, Tjandra JJ, Stacker SA, et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 1989; 67 (Pt 3): 183-95
126. Xing PX, Prenzoska J, McKenzie IF. Epitope mapping of antibreast and anti-ovarian mucin monoclonal antibodies. Mol Immunol 1992; 29 (5): 641-50
127. Kotera Y, Fontenot JD, Pecher G, et al. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994; 54 (11 ): 2856-60
128. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 1996; 32A(8): 1325-31
129. Jerome K, Barnd D, Bendt K, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991 ; 51:2908-16
130. Barnd DL, Kerr LA, Metzgar RS, et al. Human tumor-specific cytotoxic T cell lines generated from tumor- draining lymph node infiltrate. Transplant Proc 1988; 20 (2): 339-41
131. loannides CG, Fisk B, Jerome KR, et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 1993; 151 (7): 3693-703
132. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993; 151 (3): 1654-62
133. Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995; 155 (10): 4766-74
134. Xing PX, Apostolopoulos V, Michaels M, et al. Phase I study of synthetic MUC1 peptides in cancer. Int J Oncol 1995; 6: 1283-9
135. Goydos JS, Elder E, Whiteside TL. et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63(1): 298-304
136. Apostolopoulos V, Pietersz GA, Xing PX, et al. The immunogenicity of MUC1 peptides and fusion protein. Cancer Lett 1995; 90(1): 21-6
137. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996; 14 (9): 930-8
138. McKenzie IF, Apostolopoulos V. Lees C, et al. Oxidised mannan antigen conjugates preferentially stimulate Tl type immune responses. Vet Immunol Immunopathol 1998; 63 (1-2): 185-90
139. Pietersz GA, Li W, Popovski V, et al. Parameters for using mannan-MUCl fusion protein to induce cellular immunity. Cancer Immunol Immunother 1998; 45 (6): 321-6
140. Karanikas V, Hwang LA, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUCl fusion protein. J Clin Invest 1997; 100(11): 2783-92
141. Adluri S.GilewskiT, ZhangS,etal. Specificity analysis of sera from breast cancer patients vaccinated with MUCI -KLH plus QS-21. Br J Cancer 1999; 79 ( 11 -12): 1806-12
142. Springer GF. Desai PR, Spencer BD, et al. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced breast carcinoma. Cancer Detect Prev 1995; 19 (4); 374-80
143. MacLean GD, Reddish M, Koganty RR, et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol Immunother 1993; 36 (4): 215-22
144. Berd D, Mastrangelo MJ, Engstrom PF, et al. Augmentation of the human immune response by cyclophosphamide. Cancer Res 1982; 42 (11): 4862-6
145. Berd D, Maguire HC, Jr., Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44 (11): 5439-43
146. MacLean GD, Miles DW, Rubens RD, et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19 (4): 309-16
147. MacLean GD, Reddish MA, Koganty RR, et al. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19(1): 59-68
148. Sandmaier BM, Oparin DV, Holmberg LA, et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22 (1): 54-66
149. Esteban JM, Felder B, Ahn C, et al. Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients [see comments]. Cancer 1994; 74 (5): 1575-83
150. Robbins PF, Eggensperger D, Qi CF, et al. Definition of the expression of the human carcinoembryonic antigen and nonspecific cross-reacting antigen in human breast and lung carcinomas. Int J Cancer 1993; 53 (6): 892-7
151. Pignatelli M, Durbin H, Bodmer WF. Carcinoembryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions. Proc Natl Acad Sci US A 1990; 87 (4): 1541-5
152. Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57 (2): 327-34
153. Von Kleist S, Burtin P. Antigens cross-reacting with CEA. In: Herberman RB, Mclntire KR, editors. Immunodiagnosis of cancer. New York: Marcel Dekkar, 1979: 322-41
154. Mavligit GM, Stuckey S. Colorectal carcinoma. Evidence for circulating CEA-anti-CEA complexes. Cancer 1983; 52 (1): 146-9
155. Fuchs C, Krapf F. Kern P, et al. CEA-containing immune complexes in sera of patients with colorectal and breast canceranalysis of complexed iminunoglobulin classes. Cancer Immunol Immunother 1988; 26 (2): 180-4
156. Foon KA, Chakraborty M, John WJ, et al. Immune response to the carcinoembryonic antigen in patients treated with an antiidiotype antibody vaccine. J Clin Invest 1995; 96(1): 334-42
157. Foon KA, John WJ, Chakraborty M. et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997; 3 (8): 1267-76
158. Bhattacharya-Chatterjee M. Foon KA, Kohler H. Anti-idiotype monoclonal antibodies as vaccines for human cancer. Int Rev Immunol 1991: 7 (4): 289-302
159. Bhattacharya-Chatterjee M, Foon KA. Anti-idiotype antibody vaccine therapies of cancer. Cancer Treat Res 1998; 94:51-68
160. Kantor J, Irvine K, Abrams S, et al. Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine (see comments], J Natl Cancer Inst 1992; 84(14): 1084-91
161. Kantor J, Irvine K, Abrams S, et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 1992; 52 (24): 6917-25
162. Schlom J, Kantor J, Abrams S, et al. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res Treat 1996; 38 (1): 27-39
163. Tsang KY, Zaremba S, Nieroda ÇA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine [see comments], J Natl Cancer Inst 1995; 87 (13): 982-90
164. Wong C, Morse M, Nair SK. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother 1998; 21 ( 1 ): 32-40
165. Alters SE, Gadea JR, Philip R. Immunotherapy of cancer, generation of CEA specific CTL using CEA peptide pulsed dendritic cells. In: Castagnoli R, editor. Dendritic cells in fundamental and clinical immunology. New York: Plenum Press, 1997:519-24
166. Morse MA, Deng Y, Coleman D, et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1 (-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen |In process citation]. Clin Cancer Res 1999; 5 (6): 1331-8
167. Bartek J, Bartkova J. Vojtesek B, et al. Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int J Cancer 1990; 46: 839-44
168. Horak E, Smith K, Bromley L, et al. Mutant p53, EOF receptor and c-erbB-2 expression in human breast cancer. Oncogene 1991; 6: 2277-84
169. Davidoff A, Kerns B, Pence J, et al. p53 alterations in all stages of breast cancer. J Surg Oncol 1991 ; 48: 260-7
170. Fernando S, Wu X, McKenzie P, et al. Immunohistochemical detection of p53 protein expression in mammary carcinoma: a study of 80 cases. Pathology 1995; 27: 365-9
171. Lisboa B, Vogtlander S, Güster T, et al. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer. Virchows Arch 1997:431:375-81
172. Molina R, Segui M, Climent M, et al. p53 oncoprotein as a prognostic indicator in patients with breast cancer. Anticancer Res 1998; 18:507-11
173. Yanuck M, Carbone DP, Pendleton CD, et al. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993; 53 (14); 3257-61
174. Noguchi Y, Chen YT, Old LJ. A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci US A 1994; 91 (8): 3171-5
175. Noguchi Y, Richards EC, Chen YT, et al. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A 1995; 92 (6): 2219-23
176. Mayordomo JI, Loftus DJ, Sakamoto H, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptidebased vaccines. J Exp Med 1996; 183 (4): 1357-65
177. Crawford LV, Pirn DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30 (4); 403-8
178. Lubin R, Schlichtholz B, Teillaud JL, et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1995; 1 (12): 1463-9
179. Tilkin AF, Lubin R, Soussi T, et al. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995; 25 (6): 1765-9
180. Soussi T. The humoral response to the tumor-suppressor geneproduct p53 in human cancer: implications for diagnosis and therapy. Immunol Today 1996; 17 (8): 354-6
181. Ralhan R, Nath N, Agarwal S, et al. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 1998; 4 (9): 2147-52
182. Gnjatic S, Cai Z, Viguier M, et al. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160(1): 328-33
183. Theobald M, Biggs J, Dittmer D, et al. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 1995; 92 (26): 11993-7
184. Roth J, Dittmer D, Rea D, et al. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93 (10): 4781-6
185. Tuting T, DeLeo AB, Lotze MT, et al. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or self antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27 (10): 2702-7
186. Ben-Hur H, Ben-Meir A, Hagay Z, et al. Tumor-preventive effects of the soluble p53 antigen on chemically-induced skin cancer in mice. Anticancer Res 1998; 18 (6A): 4237-41
187. Wikstrand CJ, McLendon RE, Friedman AH, et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997; 57 (18): 4130-40
188. Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55 (14): 3140-8
189. Cannon PM, Ellis IO, Blarney RW, et al. Expression of tumourassociated antigens in breast cancer primary tissue compared with serum levels. Eur J Surg Oncol 1993; 19 (6): 523-7
190. Croce MV, Price MR, Segal-Eiras A. Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum. Cancer Immunol Immunother 1995; 40 (2): 132-7
191. Croce MV, Colussi AG, Price MR, et al. Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study. Anticancer Res 1997; 17 (6D): 4287-92
192. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993; 54 (2): 177-80
193. Boon T, Cerottini JC, Van den Eynde B, et al. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65
194. Itoh K, Hayashi A, Nakao M, et al. Human tumor rejection antigens MAGE. J Biochem (Tokyo) 1996; 119 (3): 385-90
195. Russo V, Traversari C, Verrecchia A, et al. Expression of the MAGE gene family in primary and metastatic human breast cancer: implications for tumor antigen-specific immunotherapy. Int J Cancer 1995; 64 (3): 216-21
196. Kawamoto M, Shichijo S, Imai Y, et al. Expression of the S ART1 tumor rejection antigen in breast cancer. Int J Cancer 1999; 80(1): 64-7
197. Nakao M, Yamana H, Imai Y, et al. HLA A2601 -restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 1995; 55 (19): 4248-52
198. Shichijo S, Nakao M, Imai Y, et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187 (3): 277-88
199. Rettig WJ, Cordon-Cardo C, Koulos JP, et al. Cell surface antigens of human trophoblast and choriocarcinoma defined by monoclonal antibodies. Int J Cancer 1985; 35 (4): 469-75
200. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992; 52 (12): 3396-401
201. Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folatebinding protein. Am J Pathol 1993; 142 (2): 557-67
202. Albert! S, Miotti S, Fornaro M, et al. The Ca-MOv 18 molecule, a cell-surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochem Biophys Res Commun 1990; 171 (3): 1051-5
203. Elwood PC. Molecular cloning and characterization of the human folate-binding protein cDNA from placenta and malignant tissue culture (KB) cells. J Biol Chem 1989; 264 (25): 14893-901
204. Li PY, Del Vecchio S, Fonti R, et al. Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J Nucl Med 1996; 37 (4): 665-72
205. Peoples GE, Anderson BW, Fisk B, et al. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol 1998; 5 (8): 743-50
206. Peoples GE, Anderson BW, Lee TV, et al. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 1999; 5 (12): 4214-23
207. Kim DK, Lee TV, Castilleja A, et al. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate
208. CTL from ovarian and breast cancer patients. Anticancer Res 1999; 19 (4B): 2907-16
209. Mehta K, McQueen T, Neamati N, et al. Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells. Cell Growth Differ 1996:7(2): 179-86
210. Gottardis MM, Bischoff ED, Shirley MA, et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR- selective ligand. Cancer Res 1996; 56 (24): 5566-70
211. Bischoff ED, Gottardis MM, Moon TE, et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LCD 1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998; 58 (3): 479-84
212. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15 (2): 790-5
213. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer [see comments). J Natl Cancer Inst 1999:91 (21): 1847-56
214. Fidler U. Critical determinants of cancer metastasis: rationale for therapy. Cancer Chemother Pharmacol 1999; 43 Suppl. 5337:53-10
215. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878 (4): 236-70
216. Shalinsky DR, Brekken J, Zou H, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999; 5 (7): 1905-17
217. D'Olimpio J, Hande K, Collier M, et al. Phase I study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors. Proc Am Soc Clin Oncol 1999; 18: 160a
218. Jones L, Ghaneh P, Humphreys M, et al. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann N Y Acad Sci 1999; 880: 288-307
219. Low JA, Johnson MD, Bone EA, et al. The matrix metalloproteinase inhibitor batimaslat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice. Clin Cancer Res 1996; 2 (7): 1207-14
220. Gatto C, Rieppi M, Borsotti P, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity [In process citation]. Clin Cancer Res 1999; 5 (11): 3603-7
221. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997:79(1): 1-8
222. Pluda J. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin Oncol 1997; 24: 203-18
223. Kirn KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1992; 362: 841-4
224. Brooks PC, Strömblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96 (4): 1815-22
225. Shawver LK, Schwanz DP, Mann E, et al. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-4-(lrifluoromelhyl)-phenyl]5-methylisoxazole-4-carboxamide. Clin Can Res 1997; 3 (7): 1167-77
226. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59 (1): 99-106
227. O'Reilly MS, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2 (6): 689-92
228. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88 (2): 277-85
229. Rosenberg SA, Aebersold P, Cornelia K, el al. Gene Iransfer into humans-immunolherapy of palients with advanced melanoma, using lumor-infiltraling lymphocytes modified by retroviral gene transduction [see comments]. N Engl J Med 1990; 323 (9): 570-8
230. Tanaka K, Isselbacher K.J. Khoury G, el al. Reversal of oncogenesis by ihe expression of a major histocompalibility complex class I gene. Science 1985; 228 (4695); 26-30
231. Tanaka K, Hayashi H, Hamada C, el al. Expression of major hislocompatibility complex class I antigens as a strategy for the potentialion of immune recognition of tumor cells. Proc Natl Acad Sci U S A 1986; 83 (22); 8723-7
232. Tanaka K, Gorelik E. Waianabe M, et al. Rejeclion of B16 melanoma induced by expression of a Iransfecled major histocompatibility complex class I gene. Mol Cell Biol 1988; 8 (4): 1857-61
233. Baskar S, Azarenko V, Garcia Marshall E, et al. MHC class II-lransfecled lumor cells induce long-ierm lumor-specific immunity in autologous mice. Cell Immunol 1994; 155 (1); 123-33
234. Nabel GJ, Nabel EG, Yang ZY, el al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicily in humans. Proc Nail Acad Sci U S A 1993; 90 (23): 11307-11
235. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after Iransfer of an allogeneic class I major histocompalibility complex gene wilh DNA-liposome complexes. Proc Nail Acad Sci U S A 1996; 93 (26): 15388-93
236. Chen L, Ashe S, Brady WA, el al. Costimulation of antilumor immunity by the B7 counlerreceplor for Ihe T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71 (7): 1093-102
237. Chen L, Linsley PS, Hellstrom KE. Coslimulation of T cells for tumor immunity. Immunol Today 1993; 14(10): 483-6
238. Townsend SE, Allison JP. Tumor rejeclion after direcl costimulation of CD8+ T cells by B7- transfecled melanoma cells. Science 1993; 259 (5093): 368-70
239. Townsend SE, Su FW, Alherton JM, et al. Specificity and longevity of antilumor immune responses induced by B7- Iransfecled tumors. Cancer Res 1994; 54 (24): 6477-83
240. Yang G, Hellstrom KE, Hellstrom I, et al. Anlitumor immunily elicited by tumor cells transfecled wilh B7-2, a second ligand for CD28/CTLA-4 coslimulatory molecules. J Immunol 1995; 154(6): 2794-800
241. Li Y, Hellstrom KE, Newby SA, et al. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996; 183 (2): 639-44
242. Melero I, Bach N, Hellstrom KE, et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28 (3): 1116-21
243. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415
244. Pardoll DM. Cancer vaccines. Nature Med 1998; 4 (5 Suppl.): 525-31
245. Manome Y, Wen PY, Hershowitz A, et al. Monocyte chemoattractant protein-1 (MCP-1) gene transduction: an effective tumor vaccine strategy for non-intracranial tumors. Cancer Immunol Immunother 1995; 41 (4): 227-35
246. Davis HL, Whalen RG. DNA-based immunization. Mol Cell Biol Hum Dis Ser 1995; 5: 368-87
247. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide-mediated immunization therapy of cancer. Semin Oncol 1996; 23 (1): 135-47
248. Donnelly JJ, Ulmer JB, Shiver JW, et al. DNA vaccines. Annu Rev Immunol 1997; 15: 617-48
249. Moelling K. DNA for genetic vaccination and therapy. Cytokines Cell Mol Ther 1997; 3 (2): 127-35
250. Chattergoon M, Boyer J, Weiner DB. Genetic immunization: a new era in vaccines and immune therapeutics. Faseb J 1997; 11 (10): 753-63
251. Benton PA, Kennedy RC. DNA vaccine strategies for the treatment of cancer. Curr Top Microbiol Immunol 1998;226: 1-20
252. Kucerova L. DNA/genetic vaccination (minireview). Viral Immunol 1998; 11 (2): 55-63
253. Lai WC, Bennett M. DNA vaccines. Crit Rev Immunol 1998; 18 (5): 449-84
254. Tuteja R. DNA vaccines: a ray of hope. Crit Rev Biochem Mol Biol 1999; 34(1): 1-24
255. Conry RM, LoBuglio AF, Loechel F, et al. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther 1995; 2 (1): 59-65
256. Chen Y. Hu D. Eling DJ, et al. DNA vaccines encoding fulllength or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998; 58 (9): 1965-71
257. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188(9): 1553-61
258. Wei WZ, Shi WP, Galy A, et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81 (5): 748-54
259. Nawrath M, Pavlovic J, Dummet R, et al. Reduced melanoma tumor formation in mice immunized with DNA expressing the melanoma-specific antigen gplOO/pmell7. Leukemia 1999; 13 Suppl. 1: S48-51
260. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999; 162 (8): 4790-5
261. Hong K, Zheng W, Baker A, et al. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly (ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEES Lett 1997; 400: 233-7
262. Templeton NS, Lasic DD, Frederik PM, et al. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotech 1997; 15: 647-52
263. Liu TJ, Zhang WW, Taylor DL, et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994:54(14): 3662-7
264. Wills KM, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994; 5: 1079-88
265. Bookstein R, Deniers W, Gregory R, el al. p53 gene therapy in vivo of hepatocellular and liver-metastatic colorectal cancer. Semin Oncol 1996; 23: 66-77
266. Roth JA, Swisher SG, Meyn RE. p53 tumor suppressor gene therapy for cancer. Oncology (Hunting!) 1999; 13, 10 Suppl. 5: 148-54
267. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-91
268. Tail DL, Obermiller PS, Redlin-Frazier S, et al. A phase I trial of retroviral BRCAlsv gene therapy in ovarian cancer. Clin Cancer Res 1997; 3 (11): 1959-68
269. Tait DL, Obermiller PS, Hatmaker AR, et al. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in im-response and vector stability. Clin Cancer Res 1999; 5 (7): 1708-14
270. Tripathy D, Benz CC. Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. In: Benz CC, Liu E, editors. Oncogenes and tumor suppressor genes in human malignancies. Boston: Kluwer Academic Publishers, 1993;15-60
271. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res Treat 1998; 52: 17-28
272. Benz CC. Transcription factors and breast cancer. Endocrinerelated cancer 1998; 5: 271-82
273. Van DH, Chang LS, Hung MC. Repressed expression of the HER-2/c-erbB-2 proto-oncogene by the adenovirus Ela gene products. Oncogene 1991; 6 (2): 343-5
274. Hortobagyi GN, Hung MC, Lopez-Berestein G. A Phase I multicenter study of E1A gene therapy for patients with metastatic breast cancer and epithelial ovarian cancer that overexpresses HER-2/neu or epithelial ovarian cancer. Hum Gene Ther 1998; 9 (12): 1775-98